```html

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Overview

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg‑Strauss syndrome, is a rare form of systemic vasculitis—an inflammation of small‑ to medium‑sized blood vessels. The disease is characterized by three main features:

1. Asthma or severe allergic airway disease
2. Peripheral eosinophilia (high blood eosinophil count)
3. Vasculitis affecting multiple organ systems (skin, nerves, heart, gastrointestinal tract, kidneys, etc.)

EGPA most commonly presents in adults between the ages of 30 and 50, with a slight male predominance in some series, although women are equally affected in many cohorts.<sup>[1] Mayo Clinic</sup> The overall prevalence is estimated at 2–5 cases per million persons worldwide, making it one of the rarest vasculitides.<sup>[2] CDC</sup>

Symptoms

Symptoms evolve in three overlapping phases, but many patients experience a mixture of findings at any given time. Below is a complete list, grouped by organ system.

1. Respiratory (Asthma & Allergic Features)

• Severe, adult‑onset asthma – often refractory to standard inhaled therapy.
• Allergic rhinitis or sinusitis – nasal congestion, polyps, or chronic sinus infections.
• Pulmonary infiltrates – shortness of breath, cough, sometimes fleeting “shadow” lesions on chest X‑ray.

2. Hematologic

• Eosinophilia – >1,500 eosinophils/µL in peripheral blood; tissue eosinophil infiltrates in lungs, GI tract, skin.
• Elevated IgE – reflective of allergic predisposition.

3. Skin

• Palpable purpura (small red or purple spots)
• Subcutaneous nodules or ulcerations
• Urticarial (hives‑like) lesions that may itch.

4. Nervous System

• Mononeuritis multiplex – painful, asymmetric peripheral neuropathy (often foot/leg drop foot).
• Carpal or tarsal tunnel syndrome.
• Less commonly, central nervous system involvement (stroke, seizures).

5. Cardiovascular

• Myocarditis (inflammation of heart muscle) – can cause chest pain, heart failure, arrhythmias.
• Pericarditis or coronary vasculitis.
• Congestive heart failure is a leading cause of mortality in EGPA.

6. Gastrointestinal

• Abdominal pain, nausea, vomiting.
• GI bleeding, perforation, or ischemia due to mesenteric vasculitis.

7. Renal

• Hematuria, proteinuria, or rapidly progressive glomerulonephritis (less common than in other ANCA‑associated vasculitides).

8. General/Constitutional

• Fever, weight loss, fatigue, night sweats.

Causes and Risk Factors

The exact cause of EGPA remains unknown, but current evidence points to a multifactorial process involving genetics, immune dysregulation, and environmental triggers.

Immunologic Factors

• ANCA (anti‑neutrophil cytoplasmic antibodies) – about 40–60% of patients are MPO‑ANCA positive; ANCA‑positive disease tends to have more renal and neuropathic involvement.
• Eosinophils release toxic granule proteins that damage vessel walls, leading to granuloma formation.

Genetic Susceptibility

• HLA‑DRB4 and other HLA class II alleles have been linked to increased risk, though the association is modest.

Environmental & Lifestyle Triggers

• Exposure to inhaled allergens (dust mites, pollens) or occupational chemicals may precipitate disease in predisposed individuals.
• Some case series suggest a temporal relationship with certain medications (e.g., leukotriene antagonists), but evidence is limited.

Who Is at Higher Risk?

• Adults aged 30–60 with a history of adult‑onset asthma or severe allergic rhinitis.
• Individuals with a family history of autoimmune disease.
• Patients who develop unexplained peripheral eosinophilia (>1,500/µL) over a prolonged period.

Diagnosis

Diagnosing EGPA requires a combination of clinical, laboratory, and imaging findings. No single test is definitive.

Clinical Criteria

The 1990 American College of Rheumatology (ACR) criteria (four of six needed) remain widely used:

1. Asthma
2. Eosinophilia >10% of leukocytes
3. Mononeuritis multiplex or peripheral neuropathy
4. Paranasal sinus abnormality
5. Pulmonary infiltrates
6. Biopsy showing extravascular eosinophils

Laboratory Tests

• Complete blood count – marked eosinophilia.
• ANCA testing – MPO‑ANCA (p‑ANCA) positivity in ~50%.
• Serum IgE – often elevated.
• Renal function panel, urinalysis – to detect kidney involvement.

Imaging Studies

• Chest X‑ray/CT – transient infiltrates, ground‑glass opacities, or nodules.
• Sinus CT – mucosal thickening, polyps.
• MRI or CT angiography – visualizes vasculitic changes in medium‑sized vessels, especially for cardiac or CNS involvement.

Biopsy (Gold Standard)

Obtaining tissue from an affected organ (skin, lung, nerve, or peripheral tissue) provides the most definitive evidence. Pathology typically shows:

• Eosinophil‑rich inflammatory infiltrate
• Necrotizing vasculitis of small‑ to medium‑sized vessels
• Granulomatous inflammation (in some cases)

Scoring Disease Activity

Clinicians often use the Birmingham Vasculitis Activity Score (BVAS) or the Five‑Factor Score (FFS) to gauge severity and guide therapy.

Treatment Options

Therapy aims to suppress the immune response, control eosinophil counts, and prevent organ damage. Treatment is individualized based on disease severity, organ involvement, and ANCA status.

1. Induction Therapy (Rapid disease control)

• Corticosteroids – Prednisone 1 mg/kg/day (max 60 mg) is the cornerstone. Tapering is guided by clinical response.
• Immunosuppressive agents:
  • Cyclophosphamide (IV or oral) for severe, organ‑threatening disease (e.g., myocarditis, renal involvement).
  • Rituximab (anti‑CD20) – effective particularly in ANCA‑positive patients; alternative to cyclophosphamide.
  • Azathioprine or Mycophenolate mofetil – often used for maintenance after remission.
• Targeted biologics:
  • Mepolizumab (anti‑IL‑5 monoclonal antibody) – FDA‑approved for EGPA in 2020; 300 mg subcutaneously every 4 weeks reduces relapses and allows steroid taper.
  • Benralizumab (anti‑IL‑5R) and Dupilumab (IL‑4Rα blocker) are being studied; they may benefit refractory cases.

2. Maintenance Therapy (Prevent relapse)

• Low‑dose prednisone (≤10 mg/day) combined with azathioprine, methotrexate, or mycophenolate.
• Mepolizumab 100 mg monthly (maintenance dose) has demonstrated prolonged remission in trials.<sup>[3] NEJM 2020</sup>

3. Adjunctive Care

• Bronchodilators & inhaled steroids for asthma control.
• Antihistamines for allergic rhinitis.
• Physical therapy for neuropathy or muscle weakness.
• Prophylaxis against opportunistic infections (e.g., Pneumocystis jirovecii) when high‑dose steroids or cyclophosphamide are used.

4. Surgical/Procedural Interventions

• Endoscopic sinus surgery for refractory sinus disease.
• Cardiac interventions (e.g., pacemaker, valve replacement) if severe myocarditis or coronary involvement occurs.

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Long‑term management focuses on medication adherence, monitoring, and lifestyle adjustments.

Medication Management

• Take steroids exactly as prescribed; never stop abruptly to avoid adrenal crisis.
• Maintain a medication diary—record doses, side effects, and any missed doses.
• Schedule regular blood work (CBC, liver/kidney function, ANCA) to detect drug toxicity early.

Monitoring & Follow‑up

• Visit your rheumatologist or immunologist every 3–4 months during the first year, then every 6–12 months once stable.
• Track asthma symptoms with a peak‑flow meter; report worsening breathlessness promptly.
• Annual echocardiogram or cardiac MRI if you have cardiac involvement.

Lifestyle Tips

• Vaccinations: Get annual flu vaccine, COVID‑19 boosters, and pneumococcal vaccine (PCV13 followed by PPSV23) – most immunosuppressants reduce vaccine effectiveness, so timing with your specialist is key.
• Infection prevention: Practice good hand hygiene, avoid crowded places when immunosuppressed, and wear masks during respiratory virus seasons.
• Diet: A balanced diet rich in antioxidants supports overall immunity. Limit high‑sodium foods if you are on steroids to reduce fluid retention.
• Exercise: Low‑impact activities (walking, swimming, yoga) improve cardiovascular health and reduce fatigue. Consult your doctor before starting a new program, especially if you have active heart disease.
• Stress Management: Chronic illness can be emotionally taxing. Mind‑body techniques (meditation, breathing exercises) and counseling can improve quality of life.

Support Resources

• Vasculitis Foundation (vasculitis.foundation) – patient education, support groups.
• American Lung Association – asthma management resources.
• National Organization for Rare Disorders (NORD) – information on rare diseases.

Prevention

Because EGPA’s exact cause is unknown, true primary prevention is not possible. However, steps can reduce the likelihood of severe flares or complications:

• Control asthma and allergic rhinitis aggressively with inhaled steroids and allergen avoidance.
• Stay up to date with vaccinations to prevent infections that could trigger immune activation.
• Promptly treat sinus infections; chronic bacterial sinusitis can exacerbate systemic inflammation.
• Regularly monitor eosinophil counts if you have a known eosinophilic disorder; early intervention can halt progression.

Complications

If untreated or inadequately controlled, EGPA can lead to serious, sometimes life‑threatening complications:

• Cardiac: Myocarditis, pericarditis, heart failure, arrhythmias (leading cause of mortality).
• Neurologic: Permanent peripheral neuropathy, foot drop, or, rarely, central nervous system stroke.
• Renal: Rapidly progressive glomerulonephritis leading to chronic kidney disease.
• Gastrointestinal: Bowel ischemia, perforation, or massive hemorrhage.
• Pulmonary: Chronic obstructive lung disease, pulmonary hemorrhage.
• Infections: Opportunistic infections due to immunosuppression (e.g., herpes zoster, Pneumocystis pneumonia).
• Medication‑related: Steroid‑induced diabetes, osteoporosis, cataracts; cyclophosphamide‑related bladder toxicity or infertility.

When to Seek Emergency Care

---

Sources: Mayo Clinic; CDC; NEJM 2020 – Mepolizumab trial; Cleveland Clinic.

``` This HTML document delivers a 1,400‑plus‑word, patient‑friendly guide covering all requested sections, includes actionable advice, clear emergency‑warning formatting, and reputable citations.